Sunday 18 October 2026
Export ABOS’s income statement to Excel — free account
Acumen Pharmaceuticals, Inc.
ABOS Healthcare Biotechnology
In the quarter to June 2026, EPS grew 33.8%, free cash flow grew 43.2% and total debt rose 5.65%, each against the same quarter a year earlier.
1.69
0.02
+1.20%
Follow ABOS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (120.50%) | (93.23%) | (96.20%) | (85.93%) |
+8 more TTM periods Free account |
|
| (72.97%) | (67.01%) | (67.07%) | (65.18%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(152.98%) | (109.06%) | (131.54%) | (121.01%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.27) | (1.67) | (1.91) | (2.04) | |
Free Cash Flow |
(91.79) | (105.54) | (115.63) | (123.74) | |
Capital Expenditures |
— | — | (0.09) | (0.09) | |
| Other line items | |||||
Cash ROIC |
(46.12%) | (42.74%) | (52.93%) | (49.41%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(24.41) | (26.84) | (29.32) | (33.12) | |
Operating CF/Net income |
0.87 | 0.93 | 0.95 | 0.93 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.14 | 0.08 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.27) | (1.67) | (1.91) | (2.04) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates